Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
24.36
-0.67 (-2.68%)
Sep 3, 2026, 4:00 PM EDT - Market closed
Pelthos Therapeutics Revenue
Pelthos Therapeutics had revenue of $15.60M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $43.30M. In the year 2025, Pelthos Therapeutics had annual revenue of $16.80M.
Revenue (ttm)
$43.30M
Revenue Growth
n/a
P/S Ratio
2.15
Revenue / Employee
$470,696
Employees
92
Market Cap
93.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.80M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| ImmuCell | 30.68M |
| Verrica Pharmaceuticals | 30.32M |
| Atara Biotherapeutics | 6.19M |
| RenovoRx | 1.98M |
PTHS News
- 16 days ago - Pelthos Therapeutics Proxy statement: Proxy filing - Filings
- 16 days ago - Pelthos Therapeutics Proxy statement: Proxy filing - Filings
- 18 days ago - Pelthos Therapeutics price target lowered to $45 from $75 at Alliance Global - TheFly
- 18 days ago - Pelthos Therapeutics price target lowered to $64 from $66 at Oppenheimer - TheFly
- 21 days ago - Pelthos Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 21 days ago - Pelthos Therapeutics Earnings release: Q2 2026 - Filings
- 21 days ago - Pelthos Therapeutics Quarterly report: Q2 2026 - Filings
- 21 days ago - Pelthos Therapeutics Slides: Corporate presentation - Filings